With no news so far this quarter, so long as Neuren hit their stated timeframes, there are three potentially significant announcements that are now compressed into the next 10 weeks.
Phase2 results potentially could further support nnz-2591 as a future platform drug
Acadia q2 results may confirm yearly guidance for Daybue revenues
FDA meeting should assist to determine the next 12-24 months strategy
Should each of these three provide positive outcomes the de-risking of Neuren investment is enormous.
Share Price, page-10903
-
- There are more pages in this discussion • 1,155 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.27 |
Change
0.920(6.41%) |
Mkt cap ! $1.951B | |||
| Open | High | Low | Value | Volume |
| $14.35 | $15.27 | $14.35 | $8.720M | 579.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | $15.25 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.27 | 3638 | 4 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |